New immune therapy tested for rare, Hard-to-Treat cancer
NCT ID NCT06980077
Summary
This study is testing an immunotherapy drug called ivonescimab for people with advanced thymic carcinoma, a rare cancer, who have already tried other treatments. The main goal is to see if the drug helps shrink tumors and is safe for patients. Participants will receive the drug through an IV every three weeks for up to two years while doctors monitor their health and the cancer's response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.